Rivastigmine for the treatment of dementia associated with Parkinson’s disease
Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USAAbstract: Parkinson’s disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of pa...
Main Authors: | Jennifer L Reingold, John C Morgan, Kapil D Sethi |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2007-05-01
|
Series: | Neuropsychiatric Disease and Treatment |
Online Access: | http://www.dovepress.com/rivastigmine-for-the-treatment-of-dementia-associated-with-parkinsonrs-a982 |
Similar Items
-
Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
by: Andreas Wentrup, et al.
Published: (2008-11-01) -
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
by: Kandiah N, et al.
Published: (2017-04-01) -
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
by: Seibert J, et al.
Published: (2012-04-01) -
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
by: Yoon-Sang Oh, et al.
Published: (2015-05-01) -
Use of a rivastigmine transdermic patch in Alzheimer's disease and Parkinson's disease dementia
by: Lacramioara Perju Dumbrava, et al.
Published: (2009-03-01)